| Similar Articles |
|---|
 |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze.   |
The Motley Fool
March 9, 2010
Brian Orelli |
The Opportunity That Wasn't Roche and Biogen Idec are suspending development of ocrelizumab for rheumatoid arthritis because patients are coming down with opportunistic infections. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
November 8, 2010
Brian Orelli |
No Sticking Point Here: Pfizer's Potential Blockbuster Works Translating successful phase 2 results into a positive phase 3 trial can require a bit of luck, especially for a disease such as rheumatoid arthritis where the outcomes are somewhat subjective. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
BusinessWeek
March 14, 2005
Arnst & Barrett |
Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments |
The Motley Fool
November 10, 2009
Brian Orelli |
Small Acquisitions and the Road to Success Bristol-Myers is taking a different route to bulk up. It announced licensing of a phase 2 rheumatoid arthritis drug, ALD518, from privately held Alder Biopharmaceuticals. |
The Motley Fool
July 9, 2009
Brian Orelli |
Yes! It Can Handle the Pressure Rigel Pharmaceuticals' latest tests show that the side effects from its rheumatoid arthritis drug candidate R788 are manageable. |
The Motley Fool
June 26, 2009
Brian Orelli |
The $16 Billion Market That Could Make You Rich A large market just waiting to be taken over. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
June 13, 2008
Brian Orelli |
Some Insight Into Incyte's Data Incyte's rheumatoid arthritis drug looks promising, according to early numbers. |
The Motley Fool
December 15, 2008
Brian Orelli |
A Potentially Game-Changing MS Drug The newest data looks good, but longer studies will be the key for Novartis. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
September 8, 2008
Brian Orelli |
Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors. |
The Motley Fool
June 17, 2004
Brian Gorman |
Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
June 15, 2010
Brian Orelli |
Pfizer Focuses, Investors Should Cheer The culling of the pipeline continues at Pfizer. While that's bad news for partners that signed on with the company or with Wyeth before the merger it's a good move for Pfizer. |
The Motley Fool
June 4, 2008
Brian Orelli |
Expanding Possibilities Fail to Expand Rigel's Stock Price Rigel gets positive data on a second indication for its lead drug, R788. |
The Motley Fool
October 7, 2008
Brian Orelli |
Will a Better Drug Sell Better? Positive trial data isn't enough to significantly boost Johnson & Johnson's Remicade. |
The Motley Fool
December 22, 2009
Brian Orelli |
Some Incyte Into Why These Drugs Rock Eli Lilly jumps on the oral-drug-for-rheumatoid-arthritis bandwagon. |
The Motley Fool
February 17, 2010
Brian Orelli |
$1.24 Billion Deal. Shares Fall 9%. That Makes Sense. Rigel Pharmaceuticals signed up AstraZeneca to take over development of its phase 2 rheumatoid arthritis drug, R788, with more than $1.24 billion in potential payments, and the shares fell more than 9%. |
The Motley Fool
February 10, 2004
David Nierengarten |
The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market. |
The Motley Fool
July 29, 2009
Brian Orelli |
Ignore These Companies at Your Peril You may not want to invest in them, but don't ignore them. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
The Motley Fool
June 22, 2011
Brian Orelli |
In-Licensing to the Rescue Abbott's latest deal could help shore things up. |
The Motley Fool
April 24, 2009
Brian Orelli |
The Economy Strikes Again Amgen isn't recession-proof either. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
August 29, 2006
Brian Lawler |
More Good News for Rituxan Genentech and Biogen Idec's drug shows positive results against multiple sclerosis. Investors, take note. |
The Motley Fool
April 27, 2009
Brian Orelli |
Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA. |
The Motley Fool
September 11, 2007
Brian Orelli |
A Waiting Game for Aspreva It will be three years before Aspreva Pharmaceuticals and partner Roche evaluate results for a treatment for lupus. If and when the drug is approved, it will have to compete with a whole host of other drugs currently in trials. Investors take note. |
The Motley Fool
August 10, 2011
Brian Orelli |
A Jab a Month Is All We Ask Biogen and Abbott's new long-acting multiple sclerosis drug works, but it has side effects. |
The Motley Fool
January 21, 2011
Brian Orelli |
Trouble in Tysabri Land? Patient additions for a drug from Biogen Idec and Elan are slowing down. |
The Motley Fool
April 12, 2011
Brian Orelli |
How Significant Is 'Statistically Significant' for Biogen? Biogen could have a third multiple sclerosis blockbuster on its hands. |
The Motley Fool
April 24, 2009
Brian Orelli |
Great Drugs Not Living Up to Their Potential How well a drug works is not the most important thing to consider when investing. Drugs that work don't always become blockbusters. |
The Motley Fool
July 17, 2009
Brian Orelli |
Tysabri Is Back! News about Biogen Idec and Elan's multiple sclerosis drug revenues, as well as those of Pfizer and Teva. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
March 26, 2009
Brian Orelli |
R&D Your Way to Higher Sales Biogen is trying to lower side effects to increase sales. |
The Motley Fool
January 16, 2008
Brian Lawler |
More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note. |
The Motley Fool
August 26, 2008
Brian Lawler |
FDA Changes Course for Elan and Biogen Idec The agency takes a different tack with one of the partnership's top drugs. |
BusinessWeek
March 21, 2005
Catherine Arnst |
On The Hot Seat At Biogen How Biogen CEO Jim Mullen managed a drug crisis after alarming news broke that the multiple sclerosis drug Tysabri may cause a deadly brain infection. |
The Motley Fool
May 28, 2010
Brian Orelli |
Innovators Will Rule the Economic Crisis Roche's CEO says two areas of health care can prosper. I agree. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
The Motley Fool
October 15, 2007
Brian Lawler |
PDL BioPharma's Best Hope The data on daclizumab for multiple sclerosis is encouraging. Investors, take note. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
The Motley Fool
October 24, 2007
Brian Lawler |
Biogen's Brisk Business Following a rumor-filled and busy couple of weeks, Biogen releases its third-quarter financial results. |
The Motley Fool
June 30, 2009
Brian Orelli |
Here We Go Again With Tysabri The number of patients on Biogen Idec's and Elan's multiple sclerosis drug, Tysabri, that have gotten progressive multifocal leukoencephalopathy since the drug was reintroduced to the market has reached double digits. |
Chemistry World
February 4, 2009
Matt Wilkinson |
GSK targets autoimmune biologics GSK recently signed seven drug development deals that could see the company release a suite of drugs to treat inflammatory diseases ranging from rheumatoid arthritis to lupus. |
The Motley Fool
March 11, 2005
Karl Thiel |
Better Times at Biogen IDEC Is now the time to buy this pharmaceutical? |
